Gritstone bio (GRTS)
(Real Time Quote from BATS)
$0.81 USD
0.00 (-0.42%)
Updated Apr 29, 2024 03:14 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GRTS 0.81 0.00(-0.42%)
Will GRTS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GRTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GRTS
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
GRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Other News for GRTS
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
Gritstone Oncology Announces Board of Directors Changes
Gritstone appoints Stephen Webster to board of directors
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Gritstone publishes interim results from Phase 1/2 study of SLATE